CORE Biomedicine applies a lineage-based therapeutic approach to identify and target core biological pathways that define cancer cell identity, aiming to discover first- and best-in-class oncology medicines. The company intends to expand potential patient populations beyond genomics-defined groups by focusing on lineage drivers. CORE was founded by former leaders of H3 Biomedicine and operates in Boston, Tokyo and Suzhou. Following its $21 million Series A and an AMED grant to its Japanese subsidiary, CORE says it will use the funds to advance lead programs through discovery and early clinical development and to strengthen collaborations with Japanese academic and clinical partners. The company positions itself as building an innovative precision medicine business leveraging the global biotech ecosystem.

Total raised

$21M

Funding rounds

3

Latest round

Series A

Latest activity

Jul 2026